Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with MTF Biologics for demineralized bone matrix (DBM). MTF Biologics is a global non-profit organization that provides one of the orthopaedic industry’s largest portfolios of allograft tissue.

Bone Biologics is developing a bone graft substitute product consisting of rhNELL-1 and a carrier, to be supplied by MTF Biologics, for the initiation and improvement of bone formation. This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients.

“This DBM supply agreement is an important milestone that allows us to advance rhNELL-1 for the $3 billion spine fusion market, with the goal of developing a product with compelling features and benefits versus existing commercial products,” said Jeff Frelick, chief executive officer of Bone Biologics. “As we prepare to commence human clinical studies, we are delighted to partner with MTF Biologics, a highly-regarded industry innovator whose bone matrix will now comprise half of our combination product.”